Late-course three-dimensional conformal concurrent chemoradiotherapy for 31 patients with non-small cell lung carcinoma
10.3781/j.issn.1000-7431.2008.11.023
- Author:
Lu-Qi XING
1
Author Information
1. Department of Radiation Oncology
- Publication Type:Journal Article
- Keywords:
Carcinoma, non-small cell lung;
Prognosis;
Radiotherapy, conformal
- From:
Tumor
2008;28(11):1004-1007
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To compare the therapeutic effects and adverse reaction of late-course three-dimensional conformal concurrent chemoradiotherapy (3DCRT) and conventional concurrent chemoradiotherapy on stage III non-small cell lung carcinoma. Methods: This study retrospectively analyzed the clinical data from 87 cases with stage III non small cell lung carcinoma. The patients were randomly divided into 3DCRT group (group A, n = 31) and conventional concurrent chemoradiotherapy group (group B, n = 56). Group A was given docetaxel 40 mg once a week for 4-6 times and concurrent radiotherapy at 40 Gy followed by 3DCRT at a total dose of 70-74 Gy. Two weeks after radiotherapy, patients received carboplatin at 300 mg/m2 and docetaxel at 75 mg/m2. Four weeks were regarded as one cycle and the chemotherapy lasted for 4 weeks. Group B were treated with conventional radiotherapy at a total dose of 60-64 Gy. The chemotherapy regimen was the same with group A. Results: This study followed up 87 cases of NSCLC patients for 24 to 36 months. The complete and partial response (CR + PR) rate of group A and group B were 80.65% and 76.56%, respectively. one-and 2-year survival rates were 51.61% and 35.48% for group A, and 35.71% and 17.86% for group B. The difference was not significant between the two groups. The incidences of acute irradiation esophagitis, acute radiation pneumonitis, and myelosuppression were 58.06%, 6.45%, and 54.83% for group A and 79.64%, 16.07%, 85.71% for group B. The difference was not statistically significant. Conclusion: The therapeutic effects of 3DCRT are better than those of conventional concurrent chemoradiotherapy, but the incidence rates of adverse reactions do not increased.
